Risk factor correlates of body mass index. Canadian Heart Health Surveys Research Group.

Simon W. Rabkin(University of British Columbia), Bruce Reeder(Northern Health), Y Chen, L Liu, Lawrence A. Leiter(St. Michael's Hospital)

PubMed

July 1, 1997

Cited by 61

Related Papers

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

|New England Journal of Medicine|2018|6.3k

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

|New England Journal of Medicine|2012|2k

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

|The Lancet|2018|1.8k

Dose-response issues concerning physical activity and health: an evidence-based symposium

|Medicine & Science in Sports & Exercise|2001|840

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

|The Lancet Diabetes & Endocrinology|2019|673